According to our study's results, the most common cause of SUTI in acute spinal cord injury
patients was E.
The prevalence of orthostatic hypotension during physiotherapy treatment in patients with an acute spinal cord injury
A review of the Acute Spinal Cord Injury
products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
This study attempted to address the situation by reviewing 101 cervical SCI patients managed at the acute spinal cord injury
(ASCI) unit at Groote Schuur Hospital (GSH).
In addition to ALS, the company is also in a Phase I NSI-566 trial in chronic spinal cord injury at UC San Diego School of Medicine, and is targeting other major central nervous system conditions, such as ischemic stroke and acute spinal cord injury
Garr will provide an overview of the company's upcoming NSI-566 cell therapy clinical trials, including ALS Phase II, ischemic stroke Phase I/II, and chronic and acute spinal cord injury
We expect to begin a pilot study in humans for acute spinal cord injury
by early 2012 and as our pipeline is advancing, we need to continue to build our leadership team.
ASCENT-ASCI is a Phase 2 clinical trial evaluating SUN13837, an investigational medication being developed to improve neurological function in patients with newly diagnosed acute spinal cord injury
GlobalData, the industry analysis specialist, has released its new report, Acute Spinal Cord Injury
(ASCI) Therapeutics - Pipeline Assessment and Market Forecasts to 2017.
This study now demonstrates the potential effectiveness of NSI-566 cells in treating acute spinal cord injury
Geron to Study GRNOPC1 in Patients with Acute Spinal Cord Injury
Resnick also in a statement said there was not enough data by way of studies for an official recommendations regarding the use of hypothermia in patients with acute spinal cord injury
or to support the belief in the medical community that early surgical decompression within the first 24 hours leads to improved outcome.
By 2011, the total addressable market for acute spinal cord injury
will be approximately $10.
The Company is developing additional neurointerventional products, including the Andara[TM] Oscillating Field Stimulator (OFS[TM]), which is an investigational device for the treatment of acute spinal cord injury
April 23, 2012 /PRNewswire/ --Today, Asubio announced the initiation of a landmark Phase 2 clinical trial of SUN13837, an investigational medication being developed to improve neurological function in patients with newly diagnosed acute spinal cord injury